O	0	3	The	The	DT	B-NP
O	4	9	Acute	Acute	JJ	I-NP
O	10	18	Dialysis	Dialysis	NN	I-NP
O	19	26	Quality	Quality	NN	I-NP
O	27	37	Initiative	Initiative	NN	I-NP
O	37	38	-	-	HYPH	B-NP
O	38	39	-	-	SYM	I-NP
O	39	43	part	part	NN	B-NP
O	44	46	IV	IV	CD	I-NP
O	46	47	:	:	:	O
B-Multi-tissue_structure	48	57	membranes	membrane	NNS	B-NP
O	58	61	for	for	IN	B-PP
O	62	66	CRRT	CRRT	NN	B-NP
O	66	67	.	.	.	O

O	68	71	The	The	DT	B-NP
B-Multi-tissue_structure	72	86	extracorporeal	extracorporeal	JJ	I-NP
I-Multi-tissue_structure	87	95	membrane	membrane	NN	I-NP
O	96	100	used	use	VBN	B-VP
O	101	103	in	in	IN	B-PP
O	104	105	a	a	DT	B-NP
O	106	116	continuous	continuous	JJ	I-NP
B-Organ	117	122	renal	renal	JJ	I-NP
O	123	134	replacement	replacement	NN	I-NP
O	135	142	therapy	therapy	NN	I-NP
O	143	144	(	(	(	O
O	144	148	CRRT	CRRT	NN	B-NP
O	148	149	)	)	)	O
O	150	153	for	for	IN	B-PP
O	154	157	the	the	DT	B-NP
O	158	167	treatment	treatment	NN	I-NP
O	168	170	of	of	IN	B-PP
O	171	172	a	a	DT	B-NP
O	173	183	critically	critically	RB	I-NP
O	184	187	ill	ill	JJ	I-NP
O	188	195	patient	patient	NN	I-NP
O	196	200	with	with	IN	B-PP
O	201	206	acute	acute	JJ	B-NP
B-Organ	207	212	renal	renal	JJ	I-NP
O	213	220	failure	failure	NN	I-NP
O	221	222	(	(	(	O
O	222	225	ARF	ARF	NN	B-NP
O	225	226	)	)	)	O
O	227	229	is	be	VBZ	B-VP
O	230	237	vitally	vitally	RB	B-ADJP
O	238	247	important	important	JJ	I-ADJP
O	248	251	for	for	IN	B-PP
O	252	259	several	several	JJ	B-NP
O	260	267	reasons	reason	NNS	I-NP
O	267	268	,	,	,	O
O	269	278	including	include	VBG	B-PP
O	279	282	its	its	PRP$	B-NP
O	283	292	influence	influence	NN	I-NP
O	293	295	on	on	IN	B-PP
O	296	312	biocompatibility	biocompatibility	NN	B-NP
O	313	316	and	and	CC	I-NP
O	317	323	filter	filter	NN	I-NP
O	324	335	performance	performance	NN	I-NP
O	335	336	.	.	.	O

O	337	340	The	The	DT	B-NP
O	341	349	clinical	clinical	JJ	I-NP
O	350	359	relevance	relevance	NN	I-NP
O	360	362	of	of	IN	B-PP
B-Multi-tissue_structure	363	371	membrane	membrane	NN	B-NP
O	371	372	-	-	HYPH	B-NP
O	372	379	related	relate	VBN	I-NP
O	380	396	biocompatibility	biocompatibility	NN	I-NP
O	397	404	markers	marker	NNS	I-NP
O	405	418	traditionally	traditionally	RB	B-VP
O	419	423	used	use	VBN	I-VP
O	424	426	in	in	IN	B-PP
O	427	434	chronic	chronic	JJ	B-NP
O	435	447	hemodialysis	hemodialysis	NN	I-NP
O	448	455	remains	remain	VBZ	B-VP
O	456	463	unclear	unclear	JJ	B-ADJP
O	464	466	in	in	IN	B-PP
O	467	471	CRRT	CRRT	NN	B-NP
O	471	472	.	.	.	O

O	473	481	Numerous	Numerous	JJ	B-NP
O	482	492	approaches	approach	NNS	I-NP
O	493	496	may	may	MD	B-VP
O	497	499	be	be	VB	I-VP
O	500	504	used	use	VBN	I-VP
O	505	507	to	to	TO	B-VP
O	508	514	assess	assess	VB	I-VP
B-Multi-tissue_structure	515	523	membrane	membrane	NN	B-NP
O	524	527	and	and	CC	I-NP
O	528	534	filter	filter	NN	I-NP
O	535	546	performance	performance	NN	I-NP
O	547	549	in	in	IN	B-PP
O	550	554	CRRT	CRRT	NN	B-NP
O	554	555	,	,	,	O
O	556	559	but	but	CC	O
O	560	562	no	no	DT	B-NP
O	563	571	specific	specific	JJ	I-NP
O	572	583	methodology	methodology	NN	I-NP
O	584	586	is	be	VBZ	B-VP
O	587	595	accepted	accept	VBN	I-VP
O	596	602	widely	widely	RB	B-ADVP
O	603	605	at	at	IN	B-PP
O	606	613	present	present	JJ	B-ADJP
O	613	614	.	.	.	O

O	615	623	Although	Although	IN	B-SBAR
O	624	625	a	a	DT	B-NP
O	626	635	potential	potential	JJ	I-NP
O	636	643	benefit	benefit	NN	I-NP
O	644	646	of	of	IN	B-PP
O	647	654	certain	certain	JJ	B-NP
B-Multi-tissue_structure	655	664	membranes	membrane	NNS	I-NP
O	665	669	used	use	VBN	B-VP
O	670	673	for	for	IN	B-PP
O	674	678	CRRT	CRRT	NN	B-NP
O	679	681	is	be	VBZ	B-VP
O	682	692	adsorptive	adsorptive	JJ	B-NP
O	693	700	removal	removal	NN	I-NP
O	701	703	of	of	IN	B-PP
O	704	716	inflammatory	inflammatory	JJ	B-NP
O	717	726	mediators	mediator	NNS	I-NP
O	726	727	,	,	,	O
O	728	732	this	this	DT	B-NP
O	733	738	issue	issue	NN	I-NP
O	739	742	has	have	VBZ	B-VP
O	743	746	not	not	RB	I-VP
O	747	751	been	be	VBN	I-VP
O	752	760	assessed	assess	VBN	I-VP
O	761	770	carefully	carefully	RB	B-ADVP
O	771	773	in	in	IN	B-PP
O	774	778	well	well	RB	B-NP
O	778	779	-	-	HYPH	I-NP
O	779	787	designed	design	VBN	B-VP
O	788	796	clinical	clinical	JJ	B-NP
O	797	803	trials	trial	NNS	I-NP
O	803	804	.	.	.	O

O	805	810	These	These	DT	B-NP
O	811	814	and	and	CC	O
O	815	820	other	other	JJ	B-NP
O	821	827	issues	issue	NNS	I-NP
O	828	834	should	should	MD	B-VP
O	835	837	be	be	VB	I-VP
O	838	841	the	the	DT	B-NP
O	842	849	subject	subject	NN	I-NP
O	850	852	of	of	IN	B-PP
O	853	859	future	future	JJ	B-NP
O	860	868	clinical	clinical	JJ	I-NP
O	869	877	research	research	NN	I-NP
O	878	885	efforts	effort	NNS	I-NP
O	885	886	.	.	.	O

